Paper39625587
CAR T-cell therapy to treat multiple myeloma: current state and future directions.
Reddy ST and 2 others. Cancer Metastasis Rev, 2024. Cited by 9 papers, by iCite.
Cite this record
ConductScience Library. CAR T-cell therapy to treat multiple myeloma: current state and future directions. Papers, record 39625587. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39625587
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Multiple Myeloma | Major topic |
| Immunotherapy, Adoptive | Major topic |
| Receptors, Chimeric Antigen | Major topic |
| Humans | |
| Animals | |
| T-Lymphocytes |
Source PubMed
References106
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37592106 | Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. | Nat Med | 2023 | https://conductscience.org/library/papers/37592106 | PubMed |
| 2 | 31042825 | Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. | N Engl J Med | 2019 | https://conductscience.org/library/papers/31042825 | PubMed |
| 3 | 33626253 | Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. | N Engl J Med | 2021 | https://conductscience.org/library/papers/33626253 | PubMed |
| 4 | 36623248 | Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium. | J Clin Oncol | 2023 | https://conductscience.org/library/papers/36623248 | PubMed |
| 5 | 37558706 | Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. | Blood Cancer J | 2023 | https://conductscience.org/library/papers/37558706 | PubMed |
| 6 | 34175021 | Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. | Lancet | 2021 | https://conductscience.org/library/papers/34175021 | PubMed |
| 7 | 35658469 | Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. | J Clin Oncol | 2023 | https://conductscience.org/library/papers/35658469 | PubMed |
| 8 | 37272512 | Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. | N Engl J Med | 2023 | https://conductscience.org/library/papers/37272512 | PubMed |
| 9 | 36762851 | Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. | N Engl J Med | 2023 | https://conductscience.org/library/papers/36762851 | PubMed |
| 10 | 28726797 | Multiple myeloma. | Nat Rev Dis Primers | 2017 | https://conductscience.org/library/papers/28726797 | PubMed |
| 11 | 27511158 | International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. | Lancet Oncol | 2016 | https://conductscience.org/library/papers/27511158 | PubMed |
| 12 | 26763514 | Multiple Myeloma: Diagnosis and Treatment. | Mayo Clin Proc | 2016 | https://conductscience.org/library/papers/26763514 | PubMed |
| 13 | 33602913 | Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. | Blood Cancer J | 2021 | https://conductscience.org/library/papers/33602913 | PubMed |
| 14 | 28187291 | The Principles of Engineering Immune Cells to Treat Cancer. | Cell | 2017 | https://conductscience.org/library/papers/28187291 | PubMed |
| 15 | 31848460 | Engineering strategies to overcome the current roadblocks in CAR T cell therapy. | Nat Rev Clin Oncol | 2020 | https://conductscience.org/library/papers/31848460 | PubMed |
| 16 | 28541315 | Therapeutic T cell engineering. | Nature | 2017 | https://conductscience.org/library/papers/28541315 | PubMed |
| 17 | 26169254 | Engineering CAR-T cells: Design concepts. | Trends Immunol | 2015 | https://conductscience.org/library/papers/26169254 | PubMed |
| 18 | 33824268 | CAR-T cell therapy: current limitations and potential strategies. | Blood Cancer J | 2021 | https://conductscience.org/library/papers/33824268 | PubMed |
| 19 | 27412889 | T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. | Blood | 2016 | https://conductscience.org/library/papers/27412889 | PubMed |
| 20 | 38307865 | GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. | Blood Cancer J | 2024 | https://conductscience.org/library/papers/38307865 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42375393 | Development of chimeric antigen receptors targeting the γδ T cell receptor. | Mol Ther Oncol | 2026 | https://conductscience.org/library/papers/42375393 | PubMed |
| 42137138 | Efficacy and safety of CD38-directed CAR-T cell therapy for multiple myeloma: a systematic review and meta-analysis. | Front Oncol | 2026 | https://conductscience.org/library/papers/42137138 | PubMed |
| 41702648 | Corticosteroids ameliorate CAR T-cell-induced cytokine-release syndrome without inhibiting multiple myeloma treatment. | J Immunother Cancer | 2026 | https://conductscience.org/library/papers/41702648 | PubMed |
| 41654863 | Ubiquitin-centered post-translational modification crosstalk orchestrates tumor immunity and immunotherapy response. | Exp Hematol Oncol | 2026 | https://conductscience.org/library/papers/41654863 | PubMed |
| 41488642 | CAR-γδ T cells: a new paradigm of programmable innate immune sentinels and their systemic applications in cancer and beyond. | Front Immunol | 2025 | https://conductscience.org/library/papers/41488642 | PubMed |
| 41428622 | 2025 Update of Cellular Immunotherapy for Plasma Cell Disorders. | Turk J Haematol | 2026 | https://conductscience.org/library/papers/41428622 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| GPRC5D | 55507 | PubTator's text mining | https://conductscience.org/library/genes/55507 | NCBI Gene |
| NR1I3 | 9970 | PubTator's text mining | https://conductscience.org/library/genes/9970 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39625587
GET https://conductscience.org/api/papers/v1/39625587/references?page=2